About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Maryland | 23,284 Studies Near You | Clareo Health

Clinical Trials LocationsMaryland

Clinical Trials in Maryland

Discover 23,284 clinical trials near Maryland. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 4761-4780 of 23,284 trials

RECRUITINGPhase 49.8 miles

Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters

NCT05383274

Single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 65 years of age.

Urethral Stricture

Urotronic Inc.34 participantsStarted Feb 2022

Little Rock, Arkansas, United States • Orlando, Florida, United States • Tampa, Florida, United States +6 more locations

TERMINATEDPhase 312 miles

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

NCT03464097

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

Celgene550 participantsStarted Jun 2018

Peoria, Arizona, United States • Scottsdale, Arizona, United States • North Little Rock, Arkansas, United States +762 more locations

Find Trials by Condition in Maryland

Breast Cancerin Maryland Lung Cancerin Maryland Prostate Cancerin Maryland Colorectal Cancerin Maryland Melanomain Maryland Leukemiain Maryland Lymphomain Maryland Pancreatic Cancerin Maryland Ovarian Cancerin Maryland Brain Cancerin Maryland Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 117 miles

Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy

NCT03253744

Background: Prostate cancer is the second leading cause of cancer death in United States (U.S.) men. Radiation is an effective treatment for most patients with localized prostate cancer, but sometimes the tumor returns. Researchers want to see if a highly focused type of radiation can help. It is given in only 5 treatments. It is called stereotactic body radiation therapy (SBRT). Objective: To study the maximum tolerated dose and side effects of stereotactic body radiation therapy in people with a local recurrence of prostate cancer after radiation. Eligibility: Men at least 18 years old who have recurrent prostate cancer after radiation therapy and no evidence of distant metastatic disease. Design: Participants will be screened with blood tests, physical exam, and medical history. They may also have: Magnetic resonance imaging (MRI) scan of the prostate. Positron emission tomography (PET)/computed tomography (CT) scan. Participants will get an injection of 2-(3-{1-carboxy-5-\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) for the PET scan. They will lie very still on their back on the scanner table. Small samples of prostate tumor tissue will be taken by a needle through the skin or rectum to see if the cancer is in the prostate. Small metal seeds will be placed into the prostate at the same time to help guide the radiation. About 2 weeks later, participants will have a radiation treatment planning CT scan. Participants will answer questions about their urine function, bowel function, erectile function, and mood. Participants will receive SBRT. They will have 5 radiation treatments over 2 weeks. Participants will have follow-up visits. They will have a physical exam, blood tests, and questionnaires. Six months after ending SBRT, the 18F-DCFPyL PET/CT will be repeated. Participants will continue to have routine visits until two years after treatment is completed....

Prostate CancerProstatic Neoplasm

National Cancer Institute (NCI)17 participantsStarted Jul 2018

Bethesda, Maryland, United States

COMPLETEDPhase 217 miles

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease

NCT05496374

The purpose of the study is to evaluate 1. The microbiological response and clinical efficacy of SPR720 compared with placebo in participants with nontuberculous mycobacteria pulmonary disease (NTM-PD). 2. The safety and tolerability of SPR720 in participants with NTM- PD 3. The pharmacokinetic (PK) of SPR719, active moiety, following orally (po) administered prodrug SPR720 in participants with NTM-PD.

Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

Spero Therapeutics25 participantsStarted Dec 2022

Birmingham, Alabama, United States • Fresno, California, United States • Los Angeles, California, United States +25 more locations

TERMINATEDPhase 317 miles

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

NCT04459715

The primary objective of the study was to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).

Squamous Cell Carcinoma of the Head and Neck

EMD Serono Research & Development Institute, Inc.730 participantsStarted Aug 2020

Birmingham, Alabama, United States • Gilbert, Arizona, United States • Tucson, Arizona, United States +285 more locations

TERMINATEDPhase 217 miles

Futibatinib in Patients With Specific FGFR Aberrations

NCT04189445

The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients with FGFR aberrations in 3 distinct cohorts. Patients will be enrolled into one of 3 cohorts: patients with advanced, metastatic or locally-advanced solid tumors harboring FGFR1-4 rearrangements (excluding primary brain tumors and intrahepatic cholangiocarcinoma \[iCCA\]); patients with gastric or gastro-esophageal junction (GEJ) cancer harboring FGFR2 amplification; and patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements.

Advanced or Metastatic Solid TumorAdvanced or Metastatic Gastric or Gastroesophageal CancerMyeloid or Lymphoid Neoplasms (MLN)

Taiho Oncology, Inc.115 participantsStarted Aug 2020

Gilbert, Arizona, United States • Los Angeles, California, United States • Washington D.C., District of Columbia, United States +58 more locations

Active Not RecruitingPhase 119 miles

FIGHT-RP 1 Extension Study

NCT03999021

Retinitis Pigmentosa (RP) is a devastating eye disease and at present there are no known treatment options that can alter the rate of vision loss and eventual blindness. In a series of studies in animal models, the effects of exposing cones in the periphery of the retina to a large excess of oxygen results in progressive oxidative damage to cone photoreceptors and cone cell death. Cone cell death gradually spreads from the periphery of the retina toward its center, narrowing the visual field and eventually resulting in tunnel vision. Compared to control patients, those with RP showed significant reduction in the reduced to oxidized glutathione ratio (GSH/GSSG) in aqueous humor and a significant increase in protein carbonyl content. This demonstration of oxidative stress and oxidative damage in the eyes of patients with RP, suggests that oxidative damage-induced cone cell death in animal models of RP may translate to humans with RP and support the hypotheses that (1) potent antioxidants will promote cone survival and function in patients with RP and (2) aqueous GSH/GSSG ratio and carbonyl content on proteins provide useful biomarkers of disease activity in this patient population. Orally administered N-acetylcysteine (NAC) has been found to be a particularly effective antioxidant that promotes prolonged cone survival and maintenance of cone function in a mouse model of RP. Since oral and/or topical administration of NAC is feasible for long-term treatment in humans, and NAC has a good safety profile, there is good rationale to test the effect of NAC in patients with RP. Oxidative damage has been implicated in several diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD), and Idiopathic Pulmonary Fibrosis. The effect of oral NAC has been tested in these indications in several clinical trials providing extensive safety data. In COPD, NAC 600mg bid improves airway function and reduces the frequency of acute exacerbations. Doses of up to 1800mg/day have been well-tolerated in the treatment of Idiopathic Pulmonary Fibrosis. Paracetamol (acetaminophen) toxicity is treated with a loading dose of 140 mg/kg NAC followed by 70 mg/kg every 4 hours for 17 doses. Normal volunteers tolerated a dose of 11.2 grams NAC/day for three months without any serious undesirable effects and in another study a dose of 500mg/kg/day was tolerated. The most frequent adverse events associated with the oral administration of NAC are gastrointestinal in nature and include vomiting, diarrhea, stomatitis, abdominal pain and nausea (incidence rate \>1/1000 to \<1/100). Hypersensitivity reactions including anaphylactic shock and anaphylactic/anaphylactoid reaction (incidence rate \<1/10,000), dyspnea, bronchospasm (incidence rate \>1/10,000 to \<1/1000), angioedema, tachycardia, urticaria, rash and pruritus (incidence rate \>1/1000 to \<1/100) have been reported less frequently. Finally, reports of headache, tinnitus, pyrexia, blood pressure decreased (incidence rate \>1/1000 to \<1/100), face edema and hemorrhage have also been collected with oral NAC. In the FIGHT-RP 1 Study, the investigators used escalating doses of NAC effervescent tablets (from 600 mg in Cohort 1 to 1800 mg in Cohort 3). The maximum tolerated dose was 1800 mg twice a day which will be continued in this study.

Retinitis Pigmentosa

Johns Hopkins University30 participantsStarted Jun 2019

Baltimore, Maryland, United States

COMPLETEDPhase 119 miles

Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

NCT04465643

The purpose of the study is to evaluate safety and feasibility of neoadjuvant nivolumab plus ipilimumab prior to standard therapy (surgery, chemotherapy or radiation therapy) in patients with Neurofibromatosis Type 1 (NF1) and newly diagnosed pre-malignant and malignant peripheral nerve sheath tumors (MPNST) for whom surgery for resection of tumor is indicated.

Nerve Sheath Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins13 participantsStarted Jun 2021

Baltimore, Maryland, United States

COMPLETEDPhase 119 miles

Phase I Study of ETEC Vaccine

NCT01147445

The purpose of this study is to learn if a new candidate vaccine (dmLT) against ETEC (E. coli infection) is safe. This vaccine will be tested to see what effects it has on the body and the ability of the vaccine to help the body resist disease. Researchers want to find the highest dose of dmLT vaccine that can be given without causing severe side effects. Most E. coli bacteria are harmless to humans and can even be beneficial. However, some are harmful, and can cause diarrhea. About 32 healthy adults, ages 18-45, will participate in this study. This study will require volunteers to stay in the research facility for several nights. Participants will be assigned to receive 1 of 4 vaccine doses by mouth. Study procedures include: stool samples, blood samples, and documenting side effects. Participants will be involved in study related procedures for about 8 months.

Gastroenteritis Escherichia Coli

National Institute of Allergy and Infectious Diseases (NIAID)36 participantsStarted Sep 2010

Baltimore, Maryland, United States • Cincinnati, Ohio, United States

COMPLETEDPhase 330 miles

Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females

NCT05461573

This study will be in two parts, Part A and Part B. The primary objective of Part A is to evaluate the contraceptive efficacy of LPRI-CF113. The secondary objective of Part A is to evaluate the safety and tolerability of LPRI-CF113. The primary objective of Part B is to evaluate the impact of LPRI-CF113 on bone mineral density (BMD) at the lumbar spine (L1-L4) after 12 months (13 medication cycles). The secondary objective of Part B is to evaluate the impact of LPRI-CF113 on BMD and bone turnover after 12 months (13 medication cycles) at the femoral neck, total hip, and total body.

ContraceptionChange in Bone Mineral Density

Insud Pharma1,542 participantsStarted Aug 2022

Alabaster, Alabama, United States • Birmingham, Alabama, United States • Tucson, Arizona, United States +44 more locations

COMPLETEDNA31 miles

Targeted Multidomain (T-MD) Interventions for Complex Mild Traumatic Brain Injury (mTBI)

NCT04549532

Objective: This 3-year multisite RCT will determine the effectiveness of a targeted multidomain intervention (T-MD) (anxiety/mood, cognitive, migraine, ocular, vestibular; and sleep, autonomic) compared to usual care (behavioral management) in military-aged civilians with complex mTBI.

Concussion, Mild

University of Pittsburgh169 participantsStarted Jun 2021

Pittsburgh, Pennsylvania, United States • Fairfax, Virginia, United States

Active Not RecruitingPhase 399 miles

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

NCT04810078

The purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab in participants with previously treated clear cell renal cell carcinoma that is advanced or has spread. The purpose of this study's substudy is to evaluate drug level biocomparability of subcutaneous nivolumab manufactured using two different manufacturing processes.

Clear Cell Renal Cell Carcinoma

Bristol-Myers Squibb681 participantsStarted May 2021

Chicago, Illinois, United States • Buffalo, New York, United States • West Reading, Pennsylvania, United States +86 more locations

TERMINATEDPhase 2107 miles

A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

NCT04363801

A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric CancerGastric AdenocarcinomaGastroEsophageal Cancer

Leap Therapeutics, Inc.247 participantsStarted Jul 2020

Phoenix, Arizona, United States • Tucson, Arizona, United States • Duarte, California, United States +45 more locations

SUSPENDEDPhase 1/2107 miles

A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease

NCT07011771

The goal of this clinical trial is to learn about the safety of CAP-003 gene therapy in adults with GBA1 associated Parkinson's Disease. It will also provide information about whether CAP-003 demonstrates efficacy in these adults. Participants will have a single intravenous infusion of CAP-003 and visit the clinic regularly for 2 years for checkups and tests.

GBA1 Parkinson Disease

Capsida Biotherapeutics, Inc.31 participantsStarted Aug 2025

Chicago, Illinois, United States • New York, New York, United States • Philadelphia, Pennsylvania, United States +3 more locations

COMPLETEDPhase 3156 miles

Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

NCT04055090

The purpose of this study is to explore the overall safety profile and durability of efficacy of Engensis (VM202) in painful diabetic peripheral neuropathy. All subjects still in follow-up for the VMDN-003 study or who have completed the Day 270 visit within the prior 90 days will be approached to enroll in the long-term safety extension study.

Painful Diabetic NeuropathyDiabetic Neuropathy, Painful

Helixmith Co., Ltd.101 participantsStarted Feb 2019

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Sacramento, California, United States +11 more locations

COMPLETEDPhase 2165 miles

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

NCT01908777

The purpose of this study is to test the benefit of a chemotherapy drug called romidepsin in patients with T Cell Non-Hodgkin Lymphoma (T NHL) who have undergone autologous transplantation.

T Cell Non-Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center47 participantsStarted Jul 2013

Tampa, Florida, United States • Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States +7 more locations

COMPLETEDPhase 2187 miles

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

NCT05307328

This is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome caused by a non-adrenal tumor. Subjects will receive each of the following 2 treatments for 24 weeks: SPI-62 and matching placebo with the option of long-term extension.

Cushing's Syndrome ICushing Disease Due to Increased ACTH SecretionCortisol Excess+3 more

Sparrow Pharmaceuticals26 participantsStarted Sep 2022

Phoenix, Arizona, United States • Fort Myers, Florida, United States • Rochester, Minnesota, United States +9 more locations

COMPLETEDPhase 1/2187 miles

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

NCT02158858

Phase 1 Part: Open-label, sequential dose escalation study of pelabresib (CPI-0610) in patients with previously treated Acute Leukemia, Myelodysplastic/Myeloproliferative Neoplasms, and Phase 2 Part: Open-label study of pelabresib (CPI-0610) with and without Ruxolitinib in patients with Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia). Pelabresib (CPI-0610) is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

MyelofibrosisLeukemia, Myelocytic, AcuteMyelodysplastic/Myeloproliferative Neoplasm+11 more

Constellation Pharmaceuticals336 participantsStarted Jul 2014

Phoenix, Arizona, United States • Los Angeles, California, United States • Jacksonville, Florida, United States +45 more locations

Active Not RecruitingPhase 1/2202 miles

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

NCT06400303

A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Systemic Sclerosis

Systemic SclerosisSystemic Sclerosis - Diffuse CutaneousSystemic Sclerosis - 2013 ACR/EULAR Classification Criteria

Kyverna Therapeutics3 participantsStarted Aug 2024

Palo Alto, California, United States • Great Neck, New York, United States

Active Not RecruitingPhase 1229 miles

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients

NCT02500849

The purpose of the study is to evaluate the safety and feasibility of administering SB-728mR-HSPC after conditioning with busulfan.

City of Hope Medical Center12 participantsStarted Mar 2016

Duarte, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +2 more locations

PreviousPage 239 of 1165Next

in Maryland

Heart Diseasein Maryland